Venthera Revenue and Competitors

Venthera is committed to developing the first approved treatment designed for patients living with cutaneous venous malformations (VMs) and lymphatic malformations (LMs). Cutaneous LMs are fluid filled sacs that do not drain properly due to abnormalities in the lymphatic system which are present from birth. These can often lie just under the skin or involve other tissues close to the skin. Cutaneous VMs are characterized by overgrown, disorganized veins near the skin. These malformations can cause a number of clinical complications including pain, bleeding, functional impairment, and disfigurement. Many cutaneous VMs and LMs are driven by mutations in PI3K or its upstream driver, TIE2. We are currently developing a topical PI3K inhibitor in order to safely and effectively treat these lesions at their source. Venthera is a BridgeBio company.